MedTrace Logo

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Conditions

Interventions

DRUG

Daraxonrasib

oral tablets

DRUG

Elironrasib

oral tablets

DRUG

Zoldonrasib

oral tablets

DRUG

Ivonescimab

IV infusion

DRUG

Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

IV infusion

DRUG

cetuximab (Cohort C2 Only)

IV infusion

DRUG

Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)

IV infusion

DRUG

Daraxonrasib (Cohort B1 only)

oral tablets

Sponsors & Collaborators

  • Summit Therapeutics

    collaborator INDUSTRY

  • Revolution Medicines, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2029-05-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07397338 on ClinicalTrials.gov